The pharmaceutical community is excited about Retatrutide 120 , a dual-action treatment showing remarkable results in clinical research. This new compound, a GLP-1 receptor agonist alongside a GIP agent , appears to substantially decrease body size and improve metabolic function . Experts are indicating that it could offer a significant advance for